New study finds Mitopure slows immune system aging

Georg-Speyer-Haus Institute and Buck Institute reveal results of randomized, placebo-controlled MitoImmune study.

Swiss consumer biotech company Timeline today announced the successful completion of its immune aging clinical study, MitoImmune. The study found that Mitopure, a proprietary form of urolithin A, slows immune system aging by re-energizing T-cells.

T-cells, key for fighting infections and age-related diseases, decline dramatically in both number and quality with age. The study’s primary endpoints were an increase of the youthful naive CD8 T-cells, and an improvement in the mitochondrial activity of these T-cells.

Both the study primary endpoints were successfully met with Mitopure intervention compared to placebo. Other secondary endpoints including reduction of inflammaging were also met.

Timeline announces completion of its immune aging clinical study, MitoImmune, using Mitopure (proprietary Urolithin A).

“Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer. These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging,” said Chris Rinsch, Co-Founder and President of Timeline.

An intervention-based assessment of immune aging, MitoImmune was a randomized, placebo-controlled study conducted in collaboration with the Georg-Speyer-Haus Institute for Tumor and Experimental Therapy and the Buck Institute for Research on Aging. The study enrolled 50 middle-aged adults over a four-week intervention with Mitopure.

“This is groundbreaking research that helps us better understand how we can counter the age-related decline of our immune system and shows us that we can rewire our bodies defense with targeted mitochondrial interventions like Mitopure,” said Dr Eric Verdin, CEO and President of the Buck Institute.

“Our collaboration with Timeline on the MitoImmune study has provided invaluable insights into the intersection of mitochondrial health and immune function,” said Dr Dominic Denk, Principal Investigator of the MitoImmune study. “These findings may prove important for the oncology community.”

The company also revealed it has partnered on two new clinical trials in collaboration with leading research institutions to assess the impact of Mitopure on healthy aging.

In collaboration with the National Institute of Aging, Timeline is investigating the impact of Mitopure on glucose metabolism in middle-aged overweight adults. The study aims to uncover the potential of Mitopure to improve metabolic health and mitigate age-related metabolic decline.

The company is also collaborating with the National Institute of Cancer, which is evaluating the impact of Mitopure on oxidative stress in adults diagnosed with prostate cancer. This new study seeks to uncover the potential of Mitopure in managing oxidative stress and its implications for cancer patients.

Earlier this year, Timeline announced that it had raised $66 million in an oversubscribed Series D financing which included investment from Nestlé and L’Oréal Group.